According to data from the Department of Health, the secondary infection rate of the elderly in residential care homes is as high as 14%, and the research team of the Faculty of Medicine of CUHK analysed the data of more than 000,<> elderly people diagnosed with the new crown during the fifth wave of the epidemic last year and found that no matter what kind of oral new crown medicine they take, it can effectively reduce the risk of admission of the elderly in residential care homes by more than <>%. In terms of reducing the rate of severe disease, Pfizer's oral drug Paxlovid can be reduced by more than <>%, while Merck's oral drug Molnupiravir can be reduced by <>%.

Ma Hanming, Honorary Clinical Associate Professor of Geriatrics, Department of Internal Medicine and Therapeutics, Faculty of Medicine, CUHK, encouraged medical staff to prescribe oral coronavirus drugs in a timely manner for eligible elderly residential care homes to alleviate their illness and reduce the burden on the healthcare system. The study has been published in the international medical journal JAMA Network Open.

The research team of the Faculty of Medicine of CUHK found that no matter what kind of oral drug they take, it can effectively reduce the risk of admission of elderly people in residential care homes by more than 50%. (Provided by CUHK Faculty of Medicine)

From 2 February to 16 March last year, the research team of the Faculty of Medicine of CUHK analysed the data of more than 3,31 elderly people diagnosed with the novel coronavirus to study the association between taking oral antivirals and the risk of hospital admission and severe disease. Of the more than 14,000 people, 14.000% did not use the new crown oral drug, and another 61.2% used Merck's oral drug Molnupiravir and 35.5% used Pfizer's oral drug Paxlovid.

The study found that no matter what kind of oral drug the new crown was taken, it could effectively reduce the risk of admission of the elderly in residential care homes by 54%; As for reducing the rate of severe disease, the performance of Pfizer's oral drug Paxlovid was reduced by 83%; Merck's oral drug Molnupiravir can be reduced by 65%.

Yip Cheuk-fun, Assistant Professor of the Department of Internal Medicine and Therapeutics, Faculty of Medicine, CUHK, added that due to insufficient sample size, the performance of the two drugs in reducing the rate of severe disease cannot be directly compared, and it can only be concluded that taking oral drugs can reduce the hospitalization rate and severe disease rate.

96-year-old Granny Chen, who was diagnosed in March last year, bluntly said that she was very scared at that time, describing that "I haven't tried to get sick", but after taking the new crown oral medicine, the symptoms were relieved, "Eat two pills, cough is not much, become happier and happy." She added that after eating the entire course of treatment, she felt a lot more comfortable.

Ma Hanming, Honorary Clinical Associate Professor of Geriatrics, Department of Internal Medicine and Therapeutics, Faculty of Medicine, CUHK, said that according to the latest data from the Department of Health, the secondary infection rate of the elderly in residential care homes is as high as 70%, and the prescription of oral drugs for the elderly in residential care homes within five days of the appearance of symptoms has effectively reduced the condition and reduced the burden on the healthcare system.

The Hong Kong government announced the end of the flu season, the peak period lasted 7 weeks, a total of 172 lives were taken, including two children, CUHK School of Medicine developed oral formula to improve the sequelae of the new crown Dean hopes that public medical care will continue business with a bar closure order The proprietor's manager said that 9 weeks in prison was too heavy, and the appeal was commuted to 3 and 2 weeks, and the new crown epidemic showed a "small wave" Liu Yulong pointed out that it has reached the top, and there is no need to become a bird of shock